Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02887495 · ClinicalTrials.gov registry record
The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)
A clinical trial of Scleroderma, sponsored by George Washington University.
- Completed
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT02887495 is a study of Scleroderma that has completed, run by George Washington University. The registered enrollment target is 600 participants, above the 376-participant average among 23 other Scleroderma trials with a reported enrollment target (60% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02887495, a study of Scleroderma, has completed, sponsored by George Washington University.
- COMPLETED
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
The Scleroderma bioreposiTOry and Pathogenesis Study (STOP Scleroderma) will help researchers use clinical data and human biospecimens to investigate why scleroderma patients develop certain complications from their disease. Patients with confirmed scleroderma, raynauds or positive autoantibodies are invited to participate. This research may help us understand how to prevent and treat scleroderma and other diseases.
Conditions Studied
Study Locations (1)
District of Columbia
- Victoria K Shanmugam - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2014-07 |
| Est. Completion | 2022-02-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02887495
The ClinicalTrials.gov registry entry for NCT02887495 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 376-participant average among 23 other Scleroderma trials with a reported enrollment target (60% higher). The listed sponsor is George Washington University, which has 133 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Scleroderma appearing as the primary indexed condition, and to 0 interventions.
NCT02887495 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT02887495 about?
NCT02887495 is a clinical study titled "The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)". The Scleroderma bioreposiTOry and Pathogenesis Study (STOP Scleroderma) will help researchers use clinical data and human biospecimens to investigate why scleroderma patients develop certain complications from their disease. Patients with confirmed scleroderma, raynauds or positive autoantibodies ar...
What is the current status of trial NCT02887495?
This trial is currently completed. The enrollment target is 600 participants. The study started on 2014-07. Estimated completion is 2022-02-02.
What conditions does trial NCT02887495 study?
This clinical trial studies the following conditions: Scleroderma.
Who is sponsoring clinical trial NCT02887495?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02887495 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scleroderma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rheumatology Diet Study
RECRUITING
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
-
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RECRUITING · Phase 1
-
Platform Clinical Study for Conquering Scleroderma
RECRUITING · Phase 2
-
Scleroderma Registry & Repository at the Hospital for Special Surgery
RECRUITING
-
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.